ARTICLE | Management Tracks

Holt resignation leaves Amarin with third CEO in 14 months

Plus: FNIH awards Lurie Prize to Stanford’s Chang, and updates from Tectonic and Contineum

June 5, 2024 2:26 AM UTC

Patrick Holt has resigned as president and CEO of  Amarin Corp. plc (NASDAQ:AMRN) to pursue other opportunities, setting up EVP and President of the U.S. business unit Aaron Berg to become the cardiovascular company’s third CEO since March 2023, when Karim Mikhail departed amid a proxy battle with Sarissa Capital. Berg, a 12-year veteran of the company, led the company after Mikhail’s departure on an interim basis. He was previously CEO of Essentialis Inc. Shares of Amarin fell 18% Tuesday to $0.70, giving the company a market cap of about $290 million.

The Foundation for the National Institutes of Health awarded the 2024 Lurie Prize in Biomedical Sciences to Howard Chang of Stanford University. Chang and his team uncovered the role of long non-coding RNA in gene regulation and its effect on diseases such as cancer and autoimmunity. Chang is a professor of cancer research, dermatology and genetics at Stanford and an investigator at Howard Hughes Medical Institute...